Immunosuppressive Therapy for Autoimmune Myasthenia Gravis

자가면역 중증근무력증의 면역억제요법

  • Kim, Su-Yeon (Department of Neurology, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Hong, Yoon-Ho (Department of Neurology, Seoul National University College of Medicine, Seoul Municipal Boramae Hospital)
  • 김수연 (서울대학교 의과대학 신경과학교실, 서울대학교병원) ;
  • 홍윤호 (서울대학교 의과대학 신경과학교실, 서울보라매병원)
  • Published : 2007.12.30

Abstract

Autoimmune myasthenia gravis (MG) is the neuromuscular junction disorder mostly caused by antibody against the acetylcholine receptor (AChR antibody) at the muscle endplate. The goal of treatment is to induce and maintain remission, i.e., absence of symptoms, with the least cost-to-benefit ratio. Although corticosteroids are effective in inducing remission in most patients, they have numerous potentially serious adverse effects with their long-term use. In addition, some patients do not respond or are intolerant to the conventional treatment. In this article, we discuss the difficulties encountered in long-term immunosuppressive treatment of MG, and review useful tips for the use of corticosteroids. Long-term immunosuppressive agents that can be used in steroid-refractory or -dependent patients will be reviewed with their safety profiles and efficacy in MG.

Keywords